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Abstract  
Several oral “vasoactive” drugs claim to increase walking capacity in patients with 
intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline 
are the most studied molecules. Although spanning several decades, several studies 
underlying these claims were not properly designed, underpowered or showed 
clinically doubtful outcomes. The evidence for these “vasoactive” drugs has always 
been received with scepticism, creating the need for systematic reviews and meta-
analyses. This brief review discusses the benefit-risk assessment of vasoactive drugs, 
by applying a systematic review to evaluate randomized, placebo-controlled trials.  
Oral naftidrofuryl and cilostazol have an acceptable safety profile as well as sustained 
evidence (documented by Cochrane analyses) of increased walking capacity. 
Subsequently, these drugs entered recommendations for peripheral arterial disease 
(PAD). In contrast, buflomedil and pentoxifylline have limited and/or doubtful 
evidence to increase walking capacity. Moreover, there were safety concerns about 
the narrow therapeutic range of buflomedil. Most other “vasoactive” drugs were either 
inappropriately or insufficiently tested or showed no significant if not negative effects 
on IC. “Vasoactive” drugs are no substitutes for lifestyle or exercise therapy but are 
adjuvant treatment to the well-appreciated triad of cardiovascular prevention 
(antiplatelet agents, statins and ACE-inhibitors), of which statins in their own right 
have documented claims to significantly increase walking capacity.  
“Vasoactive” drugs may have a place in the pharmacological management of 
symptomatic PAD in addition to the basic cardiovascular pharmacotherapy, when 
revascularization is not indicated, when exercise therapy is not feasible or when there 
is still insufficient benefit.  
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Introduction 
Treating the symptoms of intermittent claudication (IC) with drugs has always been 
viewed with caution, because of lack of documented evidence of efficacy on 
symptoms and hard endpoints. 
The pharmacological class of peripheral vasoactive agents is heterogeneous with 
multiple physiological actions. These drugs have been heavily promoted for decades, 
but many have been questioned and few are included in current guidelines. No single 
drug has gained full and widespread acceptance for use in IC.  
Epidemiological surveys reveal that patients with peripheral arterial disease (PAD) 
and its co-morbidity are blatantly undertreated. Their risk modification is often not 
optimal and the cardiovascular co-morbidity underestimated 1.  
Finally, symptomatic PAD patients are often severely impaired as to functional status 
(walking distance) and quality of life. 
 
Standard treatment 
Lifestyle changes, management of risk factors and use of cardioprotective drugs are 
undoubtedly the first priority in the treatment of IC to inhibit progression of 
atherosclerotic disease and development of atherothrombotic complications in the 
cardiovascular tree. Basic treatment consists of an active policy of smoking cessation, 
supervised and unsupervised exercise training, control of diabetes, dyslipidemia, 
hypertension, correction of hypercoagulable states and antiplatelet therapy2-6. 
Moreover, some of these therapies, such as smoking cessation7, exercise programs8 
and statins9 also have a symptomatic effect on walking distance (WD). 
 
Revascularization 
Second, there is also the choice of endovascular or surgical revascularization.  
These procedures are readily available in most hospital settings and it is tempting to 
dilate or operate on stenotic vessels. Revascularization should only be considered 
when certain criteria are fulfilled and a global favourable benefit-risk ratio might be 
expected 10. Given the variable natural course of the disease, evaluation of the effect 
of invasive vascular therapy is complex. Long-term evaluation is needed. The clinical 
and scientific community is awaiting the results of the CLEVER (The Claudication 
Exercise Vs Endoluminal Revascularization) study 11. 
Other cardiovascular morbidity (coronary artery disease (CAD), atherosclerotic renal 
artery disease), which is closely associated with IC should be corrected, provided 
there is a prognostic potential 12.  
 
Symptomatic treatment  
Is there still a place for the pharmacological treatment of the symptoms of IC, next to 
secondary prevention and a myriad of interventional options? Some patients remain 
symptomatic even after maximal application of secondary prevention measures or 
revascularization. Some patients have contra-indications for invasive treatment or 
have a personal preference for pharmacological therapy.  
The aim is to separate the wheat from the chaff in the large class of presently 
available vasoactive drugs by determining for which substances sufficient evidence of 
symptomatic effect is available to support their use in IC patients.   
 
 How to assess risk and benefit of vasoactive drugs? 
Safety assessment 
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In most, especially older, randomized controlled trials (RCTs) of vasoactive drugs, the 
section on safety is often limited to a statement such as “the drug was well tolerated”. 
Adverse event reporting was often only based on volunteered reporting and the trials 
were too small to detect low prevalence problems. A zero numerator does not mean 
all is safe13. Especially when dealing with old products, several sources of safety data 
should be consulted. Information from national and international safety databases 
should be critically analyzed and assessed for reporting bias. Case reports of serious 
adverse reactions should be traced with classical bibliographic searches, meticulous 
checking of conferences and proceedings, references of publications (snow balling), 
contact with the original study investigators, other researchers and the manufacturer.   
 
Benefit assessment  
Since there is no gold standard for the symptomatic treatment of IC, evidence on 
efficacy can only be obtained from placebo–controlled RCTs. It is clear that patients 
should receive optimal standard treatment.  
Successful symptomatic treatment of IC means a relevant improvement in WD 
measured by a standardized exercise test. The relevance of changes of surrogate 
endpoints (temperature, viscosity) is not known as there is no correlation with clinical 
parameters.   
Reviews or meta-analyses of trials on IC should be critically appraised, as in this 
scientific field the number of narrative reviews exceeds the number of original 
studies. Special attention for trial selection, publication bias and heterogeneity is 
needed 14. 
a) The trial selection process can only be appraised, when the search strategy, 
selection criteria, and data extraction choices are explicitly mentioned. At least 2 
raters should assess the quality of the set of retrieved trials. Each study is checked for 
bias in internal and external validity 15. When results are not reported in sufficient 
detail, an attempt has to be made to contact the author(s). 
b) Publication bias in evidence based medicine is a serious limitation: presentation of 
the results can be biased or trials with negative results may not be reported.  
Publication bias can theoretically be assessed through funnel plots 16. However, the 
sample size of many studies of pharmacological treatment of IC is small. Hence 
funnel plots based on detection of a positive monotonic relationship between relative 
efficacy and sample size are of limited relevance here. All efforts should be taken to 
search for and to locate unpublished studies.   
Trials should be meticulously traced. Besides bibliographic searches for trials and 
reviews, thorough searching of trial registers, hand searching, searching of 
proceedings and conferences, meticulous checking of references of publications 
(snow balling), contact with other researchers, and with the manufacturing company 
are all necessary. 
c) Heterogeneity should always be discussed in a meta-analysis17. Clinical 
heterogeneity can be assessed qualitatively looking at similarities or differences 
between trials and can be reduced by predefined selection criteria. 
Statistical heterogeneity can be assessed graphically by forest plots with χ2 test. When 
there is an indication for significant heterogeneity the results should either not be 
summarised, or analysed with random effects models 18. 
 
Clinical relevance is a tricky issue in IC. How to define a responder? Does it mean > 
50% improvement of baseline? Is a threshold of weighted mean difference (WMD) of 
at least 25 or 50 m relevant? These questions have not yet been answered definitely, 
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as the relationship between improvement in walking distance and maintenance of 
daily life activities and quality of life19 stills needs elucidation.  
 
Results of our quest for evidence on risk and benefit of vasoactive drugs in IC 
Based on evidence from RCTs, 3 groups emerged with regard to efficacy (table): I. 
drugs with an evidence base supporting claims of efficacy, II. drugs with limited 
and/or doubtful evidence of efficacy, III. drugs with no proven evidence of efficacy.   
 
I. Drugs with an acceptable safety profile have an evidence base supporting claims of 
limited efficacy:  
Naftidrofuryl (mostly used in Europe) has evidence from a meta-analysis based on 
individual patient data of 7 trials20. Oral naftidrofuryl gives a significant improvement 
of painfree walking distance (PFWD) and maximum walking distance (MWD) over 
placebo (n=1266, WMD 48.44 m, 95%CI 35.94-60.95 and 88.9 m, 95%CI 29.94-
147.87). There is evidence for improvement of quality of life 21. Besides gastric 
problems, tolerance and safety are acceptable. A drawback of naftidrofuryl is the 
patient’s compliance with a daily dosage of 3x200 mg. Reformulation of the drug 
with prolonged action might be considered.  
Cilostazol (mostly used in the US) has evidence from a meta-analysis. Cilostazol 
2x100 mg/day gives a significant improvement of PFWD and MWD22(n= 1500, 
WMD 31.1 m, 95%CI 21.3-40.9 and 49.7 m, 95%CI 24.2-75.2, respectively). 
Cilostazol has potent antiplatelet activity and some clinical trials point into the 
direction of beneficial effect of cilostazol similar to other antiplatelet regimens23, 24 
and on top of other antiplatelets as aspirin and clopidogrel25.  
As a phosphodiesterase-inhibitor, the drug is contra-indicated in heart failure and side 
effects include headache, diarrhoea, and dizziness but the overall safety profile is 
acceptable. Nowadays naftidrofuryl and cilostazol are the best candidates for 
symptomatic treatment of IC. Both are mentioned in the SIGN 26 and TASC II 10 
guidelines. 
Statins have evidence from several RCTs for a beneficial effect on IC (PFWD: WMD 
89.76 m, 95% CI 30.05-149.47, MWD: WMD 152 m, 95% CI 32.11-271.88)9, 27-30 
besides their well known lipid lowering effects and benefit on cardiovascular and 
cerebrovascular morbidity and mortality. They also might play a beneficial role in 
pre-operative use in vascular surgery, in renal protection which further promotes them 
for standard use in the vulnerable PAD patients 31-35. Side effects include myalgia 
with risk of rhabdomyolysis, mainly in combination with other drugs, increased liver 
enzymes, central effects and polyneuritis 36. 
 
II. Drugs with limited and/or doubtful evidence:  
We briefly discuss buflomedil, registered in Europe, and pentoxifylline, registered in 
both Europe and the USA, for treatment of IC.  
For buflomedil, in a systematic review 6 trials were selected but 4 of them excluded 
because of high risk of bias 37. The 2 remaining trials randomised a total of 127 
participants to receive buflomedil or placebo for at least 3 months 38, 39. Both showed 
moderately positive results for improvement in PFWD (n=93, 75.1 m, 20.6-129.6; 
n=34, 80.6 m, 3.0-158.2, respectively) and MWD (n=93, 80.7 m, 9.4-152; n=34,171.4 
m, 51.3-291.5) with wide variation in benefit between participants. At least another 4 
unpublished studies with negative results 40-43, cited in a meta-analysis 44, exist. We 
could not retrieve the original reports for data extraction. This is a rare example of 
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documented publication bias and not just publication bias inferred from graphics or 
statistics.  
In 1999 the French government commissioned a long-term trial of buflomedil, 
coinciding with concerns about potential toxicity of the product. The Limbs 
International Medical Buflomedil Trial was a large RCT in which limited 
improvement of a composite outcome was observed 45. In the editorial 46 the results 
were interpreted much more conservatively. No safety problems were mentioned in 
the trial. However, in 2006 safety concerns were raised in several countries because of 
lethal and non-lethal neurological and cardiovascular adverse events in cases of 
accidental and voluntary overdoses and in renal insufficiency47. As a consequence, the 
300 and 600 mg forms have been withdrawn from the market, the 150 mg dosage is 
kept with the only indication of IC48 
Given the limited evidence on efficacy and the narrow therapeutic range, the present 
benefit-risk ratio of buflomedil is considered as marginal.  
With pentoxifylline several RCTs have been performed and there are at least 4 
reviews on its use in IC 49-52. The trials were of varying quality. The results were 
contradictory and in general modest. In the latest systematic review 51, only 2 of 18 
trials were of acceptable quality, providing very modest and statistically insignificant 
results for PFWD (n=150, 15m, -5-35 and n=40, -30m, -138-78 and for MWD 
(n=150, 21m, -10-52, and n=40, 69m,-44-182). In 2002, 4 new trials appeared on the 
use of pentoxifylline for IC, all performed by the same group 53-56. They report 
significant positive results for PFWD (38% increase vs placebo) and MWD (38-124% 
increase vs placebo). These trials have not yet been peer reviewed. A protocol of 
pentoxifylline in IC has been published for several years, but the systematic review  is 
still awaited 57.  
Side effects include vasomotor flushing, gastro-intestinal disturbances, bleeding, and 
hypersensitivity reactions. 
For now, there is insufficient evidence for benefit of pentoxifylline in IC.  
 
III. Drugs limited by lack of evidence: 
There is no indication for their recommendation in the treatment of IC because there 
are either no RCTs or none showing efficacy. This conclusion can be reversed by 
results of high quality trials on symptoms, disease modification, or hard endpoints.  
 
Conclusions  
1. There still is a role for symptomatic pharmacological treatment of IC in its own 
right.   
2. The drugs that currently qualify are: naftidrofuryl and cilostazol. Both have been 
analysed in a Cochrane review. In the absence of comparative head to head trials or a 
mixed method analysis, it is up to the reader to judge their benefits and risks.  
3. In general, it is not because a product is old that it should not be (re)subjected to a 
thorough review. It should be considered not to renew licenses of drugs for which we 
fail to deliver convincing evidence of a satisfactory benefit/risk ratio. This could be 
discussed in following conditions: a) initial claims of efficacy and efficiency are not 
corroborated as experience accumulates, and /or b) halted research activity fails to 
deliver confirmation of effect and/or c) no other convincing indications emerge and/or 
d. there is a toxicity or safety issue.  
4. Future trials on symptomatic treatment of IC should include walking distances 
besides quality of life.  
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5. As economic resources are limited, besides efficacy and safety, cost-effectiveness 
should be included in the analysis, based on recent data of efficacy, safety and direct 
and indirect health care costs.  
 
 
 
 
Table. Classification of vasoactive products in the symptomatic treatment of 
intermittent claudication evaluated through randomised, placebo-controlled, 
double-blind trials. 
 
I. Drugs with an evidence base supporting claims of efficacy on symptoms of IC 
cilostazol   naftidrofuryl   statins* 
 
II. Drugs with limited and/or doubtful evidence of efficacy on symptoms of IC  
angiogenesis growth factors ACE-inhibitors*  L-arginine  
aspirin*   buflomedil   Proprionyl-L-carnitine 
clopidogrel*   cloricromene   dipyridamole  
gingko biloba   mesoglycan   pentoxifylline 
picotamide   policosanol   prostaglandins 
ticlopidine*   verapamil   vitamin E    
 
III. Drugs with no evidence of efficacy on IC  
pure arteriolar vasodilators cinnarazine   cyclandelate  
isoxsuprine   ketanserin   xantinol nicotinate  
 
*: These drugs have evidence for use in the standard treatment of peripheral arterial 
disease 
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